ALX Oncology

Tomorrow at the Biotechnology Innovation Organization Investor Forum, a panel of industry experts including our Chief Financial Officer Pete Garcia will discuss the current IPO landscape and how biotech companies can best position themselves for success in today’s dynamic market. Don’t miss it if you’re attending #BIF2024! View the agenda here: https://lnkd.in/dT3zhgkY

Attending the Hanson Wade Group 6th Annual Macrophage-Directed Therapies Summit in Boston this week? Tomorrow hear from our President and Chief Scientific Officer, Jaume Pons, on how combining therapies to enhance macrophage-directed investigational treatment could offer a promising avenue in oncology. 🔍 Key Highlights: Strategizing the logical design of a combination therapy to enhance the efficacy of your macrophage-directed therapy. Weighing up the benefits and drawbacks of combination therapies to grasp their appeal. Reviewing the costs and other limiting factors associated with combination therapies. #HealthcareInnovation #CombinationTherapy #MacrophageResearch https://lnkd.in/e6rE5mX7

When scientific rationale, conviction and clinical validation converge, the opportunities are limitless. Our CEO Jason Lettmann recently discussed the incredible potential that we see in our lead investigational therapy, evorpacept, and our company’s aspirations in a fireside chat with Li Watsek at the 2024 Cantor Fitzgerald Healthcare Conference.    View the webcast here: https://bit.ly/3BhI1jX

ALX Oncology will attend the Cantor Fitzgerald Global Healthcare Conference in New York City this month. Make sure to tune into the fireside chat with our CEO, Jason Lettmann. Registration details can be found here: https://bit.ly/3MzJjcy

Today, we announced that the first patients have been dosed in an arm of the randomized UMBRELLA phase 1/2 clinical study partnered with Sanofi that is evaluating our investigational CD47 blocker evorpacept in combination with SARCLISA® (isatuximab-irfc) in patients with relapsed refractory multiple myeloma. Read more here: https://bit.ly/3ARZsr4

We’ve announced Q2 2024 financial results and recent business developments. Read more: https://bit.ly/4fDW17q

We’re excited to announce the appointment of distinguished #oncology and drug development leader Alan Sandler, M.D., to our Board of Directors. Learn more: https://lnkd.in/gm65DHbp

We’ve announced topline data from our Phase 2 ASPEN-06 clinical trial. The randomized trial demonstrated clinically meaningful improvements in overall response rate and duration of response among patients with previously treated HER2-positive advanced gastric or gastroesophageal junction (GEJ) #cancer. Learn more: https://lnkd.in/guuDFn3B  

Did you know that evorpacept has now been dosed in more than 500 patients with cancer? This unique investigational agent represents a highly differentiated CD47 blocker that combines a high-affinity CD47 binding domain with an inactivated Fc. Learn more about evorpacept here: https://bit.ly/4eCBC26

#HiringAlert! The ALX Oncology team is growing, and we invite you to join our innovative oncology company focused on delivering first-in-class therapies to patients based on science and driven by the best people. See our careers page here: https://bit.ly/3Xnjpzl